AACR-NCI-EORTC 2017: Combination Therapy With CXCR4 Inhibitor for Advanced Kidney Cancer
Adding an oral CXCR4 inhibitor (X4P-001-IO) to the tyrosine kinase inhibitor axitinib appears to be clinically active in the treatment of patients with clear cell renal cell carcinoma, according to the early findings of the dose-escalation part of a phase I/II trial presented at the American Association for Cancer Research–National Cancer Institute–European Organisation for Research and Treatment of Cancer (AACR-NCI-EORTC) International Conference on Molecular Targets and Cancer Therapeutics (Abstract B201) in Philadelphia. The 400-mg dose of X4P-001-IO was selected for use in the phase II portion of this ongoing trial.
“These results suggest that X4P-001-IO may address some of the limitations and augment the clinical utility of axitinib,” stated lead investigator Michael Atkins, MD, Deputy Director of Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, in a press release.
A total of 16 patients with histologically confirmed clear cell renal cell carcinoma were enrolled in the first part of this open-label study, receiving the combination therapy. The patients had received a median of two prior lines of therapy.
Of the patients evaluated thus far, the disease control rate was 93%, with one complete response confirmed. At data cutoff, the median duration of treatment was 22.1 weeks. The investigators noted the combination therapy inhibited CXCR4 in peripheral blood, with elevation in both white blood cell and CD34-positive cell counts. Among the most frequent treatment-related side effects were hypertension, diarrhea, fatigue, nausea, decreased appetite, headache, and dry eye.